SEC Form 4 · accession 0000899243-18-017777
Eidos Therapeutics, Inc. · EIDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hoyoung Huh
Director
Period of report
Jun 22, 2018
Accepted (ET)
Jun 22, 2018 · 6:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001731831
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.00 | Jun 22, 2018 | A | 83,720 | A | — | Jun 21, 2028 | Common Stock | 83,720 | 83,750 | D |
Explanation of responses
- F1The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 83,720 stock options (the "Grant") on June 22, 2018 (the "Grant Date"). The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following the Grant Date subject to the Reporting Person's continued service to the Issuer through each vesting date